eligibility_summary
Adults (≥18) with consent, ECOG 0–2, relapsed/refractory CD20+ B-ALL (≥5% marrow blasts or MRD≥0.1%, ≥50% blasts CD20, in 1st relapse only if CR1 ≤12 mo). Adequate organ/marrow function, EF≥50%, WBC ≤10K. Exclude: active CNS disease, unresolved ≥G2 toxicity, recent anticancer therapy/immunosuppression, transplant, severe MAb/IMiD allergy, uncontrolled infection (HBV/HCV/HIV), autoimmune disease, major CV/pulm disease, recent surgery, pregnancy, contraception required.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I, single-arm, dose-escalation trial of mosunetuzumab (RO7030816) for relapsed/refractory B-cell acute lymphoblastic leukemia. Intervention: mosunetuzumab, a subcutaneous bispecific T-cell–engaging monoclonal antibody (CD20×CD3). Mechanism of action: concurrently binds CD20 on malignant B cells and CD3 on T cells, forming an immune synapse that activates T cells (via TCR/CD3 signaling) to kill CD20+ B-ALL blasts through cytotoxicity and cytokine release. Targets: CD20-expressing B-ALL cells (≥50% blasts CD20+) and CD3 on T lymphocytes. Objectives: assess safety and define a recommended dose, secondary endpoints include CR/CRi, DOR, PFS, OS. Status: withdrawn (0 accrual).